Rede D'Or Sao Luiz SA
BOVESPA:RDOR3

Watchlist Manager
Rede D'Or Sao Luiz SA Logo
Rede D'Or Sao Luiz SA
BOVESPA:RDOR3
Watchlist
Price: 38.89 BRL -2.04% Market Closed
Market Cap: R$89B

Rede D'Or Sao Luiz SA
Investor Relations

Rede D'Or São Luiz SA stands as a prominent figure in Brazil's healthcare landscape, weaving its narrative through a network of hospitals and healthcare facilities that span the country. Founded in 1977, the company has cultivated a robust business model focused on the provision of high-quality, comprehensive healthcare services. It operates through a substantial portfolio of hospitals, oncology clinics, and surgical centers, reflecting a commitment to expanding healthcare accessibility and enhancing patient experiences. The company thrives in a space where it addresses the increasing demand for private healthcare services, driven by an aging population and growing affluence in Brazil.

The financial engine of Rede D'Or is powered by a multifaceted revenue stream predominantly comprising hospitalization and associated medical services. The company strategically leverages its vast infrastructure, clinical excellence, and brand reputation to maintain and grow its market share. Investment in state-of-the-art medical technology and facilities further supports its business model, enhancing operational efficiency and service quality. By offering a diversified range of healthcare services, the company ensures a constant and stable flow of revenue, buttressed by long-term contracts and partnerships with insurance companies. This, in turn, allows Rede D'Or to continually reinvest in expanding its network and upholding the high standards that defined its inception.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q4 2025
Call Date
Feb 26, 2026
AI Summary
Q4 2025

Record Results: Rede D'Or delivered record results in 2025, with strong growth across revenue, EBITDA, and cash generation.

Revenue Growth: Net revenue grew by 27%, while consolidated gross income reached BRL 60.4 billion.

EBITDA Expansion: Consolidated EBITDA rose 23%, with broad EBITDA (including connected assets) at BRL 11.9 billion.

Strong Cash Returns: Robust cash generation enabled BRL 1.75 billion in interest on capital and BRL 5 billion in dividends, while maintaining healthy leverage (net debt/EBITDA at 1.82x).

Operational Strength: Patient day volume reached 3 million (79% occupancy), and surgeries grew 14% to 570,000 in 2025, with a notable 19% increase in Q4.

SulAmerica Growth: Beneficiary base expanded 11.3% to 5.9 million, with a consolidated loss ratio improving to 79%.

One-Off Impacts: Q4 included BRL 89 million in conservative provisions and BRL 22 million in incentive law expenses, impacting comparability.

Positive 2026 Outlook: Management reported a strong start to 2026 in both hospital and insurance operations, emphasizing ongoing growth and efficiency.

Key Financials
Gross Consolidated Income
BRL 60.4 billion
Consolidated EBITDA
BRL 10.4 billion
Broad EBITDA (with connected assets)
BRL 11.9 billion
Interest on Capital (paid)
BRL 1.75 billion
Dividends (paid)
BRL 5 billion
Net Debt / EBITDA
1.82x
Patient Day Volume
3 million
Occupancy Rate
79%
Number of Surgeries
570,000
Oncology Hospital Invoicing Share
11%
Oncology Gross Revenue (Q4)
BRL 1.05 billion
Oncology Gross Revenue (FY)
BRL 3.9 billion
SulAmerica Beneficiary Base
5.9 million
SulAmerica Consolidated Loss Ratio
79.5%
Hospital Services Cost (Q4)
BRL 6.3 billion
Hospital Services Cost (FY)
BRL 24.4 billion
General and Administrative Expenses (Q4)
BRL 350 million
General and Administrative Expenses (FY)
BRL 1.2 billion
Hospital Services EBITDA (Q4)
BRL 2.89 billion
Hospital Services EBITDA Margin (Q4)
25%
Hospital Services EBITDA (FY)
BRL 8.142 billion
Hospital Services EBITDA Margin (FY)
25.9%
Net Consolidated Income (Q4)
BRL 1.277 billion
Adjusted Net Income (FY)
BRL 4.27 billion
SulAmerica Net Revenue (Q4)
BRL 8.55 billion
SulAmerica Net Revenue (FY)
BRL 33.168 billion
SulAmerica Adjusted EBITDA (Q4)
BRL 1.057 billion
SulAmerica Adjusted EBITDA (FY)
BRL 3.797 billion
Consolidated EBITDA
BRL 10.447 billion
Adjusted Consolidated EBITDA
BRL 11.492 billion
Consolidated Cash Position
BRL 42 billion
Net Debt
BRL 21 billion
Total Beds
13,555
Operational Beds
10,351
Earnings Call Recording
Other Earnings Calls

Management

Mr. Paulo Junqueira Moll
CEO & Member of Executive Board
No Bio Available
Mr. Otavio de Garcia Lazcano
Member of Executive Board, CFO & Investor Relations Officer
No Bio Available
Mr. Jamil Muanis Neto
Director & Member of Executive Board
No Bio Available
Ms. Raquel Reis Correa Giglio
Member of Executive Board
No Bio Available

Contacts

Address
SAO PAULO
Sao Paulo
Rua Francisco Marengo, n 1.312, Tatuape
Contacts
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett